Daewon Pharmaceutical Co., Ltd. (003220.KS)
KRW 14020.0
(-1.2%)
KRW 14020.0
(-1.2%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 116.06 Billion KRW | 29.67% |
| 2022 | 89.5 Billion KRW | 8.79% |
| 2021 | 82.27 Billion KRW | 95.7% |
| 2020 | 42.03 Billion KRW | 10.16% |
| 2019 | 38.16 Billion KRW | 191.03% |
| 2018 | 13.11 Billion KRW | 107.38% |
| 2017 | 6.32 Billion KRW | 145.23% |
| 2016 | -13.97 Billion KRW | 26.88% |
| 2015 | -19.11 Billion KRW | -4.63% |
| 2014 | -18.27 Billion KRW | -13.99% |
| 2013 | -16.03 Billion KRW | 23.72% |
| 2012 | -21.01 Billion KRW | -84.18% |
| 2011 | -11.41 Billion KRW | -26.36% |
| 2010 | -9.03 Billion KRW | -250.61% |
| 2009 | 5.99 Billion KRW | 354.29% |
| 2008 | -2.35 Billion KRW | 7.43% |
| 2007 | -2.54 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 131.5 Billion KRW | 13.3% |
| 2024 Q2 | 171.72 Billion KRW | 30.58% |
| 2023 Q2 | 98.36 Billion KRW | -8.01% |
| 2023 Q4 | 116.06 Billion KRW | 5.15% |
| 2023 FY | 116.06 Billion KRW | 29.67% |
| 2023 Q1 | 106.93 Billion KRW | 19.47% |
| 2023 Q3 | 110.38 Billion KRW | 12.22% |
| 2022 Q1 | 113.18 Billion KRW | 37.58% |
| 2022 FY | 89.5 Billion KRW | 8.79% |
| 2022 Q4 | 89.5 Billion KRW | -16.5% |
| 2022 Q3 | 107.19 Billion KRW | 1.57% |
| 2022 Q2 | 105.54 Billion KRW | -6.76% |
| 2021 FY | 82.27 Billion KRW | 95.7% |
| 2021 Q2 | 80.94 Billion KRW | 35.08% |
| 2021 Q1 | 59.92 Billion KRW | 42.54% |
| 2021 Q3 | 114 Billion KRW | 40.86% |
| 2021 Q4 | 82.27 Billion KRW | -27.84% |
| 2020 FY | 42.03 Billion KRW | 10.16% |
| 2020 Q4 | 42.03 Billion KRW | -5.3% |
| 2020 Q2 | 44.04 Billion KRW | 20.15% |
| 2020 Q3 | 44.39 Billion KRW | 0.79% |
| 2020 Q1 | 36.66 Billion KRW | -3.93% |
| 2019 Q3 | 35.56 Billion KRW | 2.65% |
| 2019 Q2 | 34.64 Billion KRW | 32.16% |
| 2019 FY | 38.16 Billion KRW | 191.03% |
| 2019 Q4 | 38.16 Billion KRW | 7.3% |
| 2019 Q1 | 26.21 Billion KRW | 99.95% |
| 2018 Q4 | 13.11 Billion KRW | 43.42% |
| 2018 FY | 13.11 Billion KRW | 107.38% |
| 2018 Q1 | -623.28 Million KRW | -109.86% |
| 2018 Q2 | 3.27 Billion KRW | 625.57% |
| 2018 Q3 | 9.14 Billion KRW | 179.09% |
| 2017 Q1 | -13.01 Billion KRW | 6.89% |
| 2017 Q4 | 6.32 Billion KRW | 179.17% |
| 2017 FY | 6.32 Billion KRW | 145.23% |
| 2017 Q2 | -1.29 Billion KRW | 90.02% |
| 2017 Q3 | 2.26 Billion KRW | 274.36% |
| 2016 Q2 | -14.64 Billion KRW | -4.45% |
| 2016 FY | -13.97 Billion KRW | 26.88% |
| 2016 Q1 | -14.01 Billion KRW | 26.68% |
| 2016 Q4 | -13.97 Billion KRW | -4.54% |
| 2016 Q3 | -13.37 Billion KRW | 8.66% |
| 2015 FY | -19.11 Billion KRW | -4.63% |
| 2015 Q3 | -12.09 Billion KRW | 17.31% |
| 2015 Q4 | -19.11 Billion KRW | -58.06% |
| 2015 Q2 | -14.62 Billion KRW | 11.14% |
| 2015 Q1 | -16.46 Billion KRW | 9.91% |
| 2014 Q1 | -21.21 Billion KRW | -32.32% |
| 2014 FY | -18.27 Billion KRW | -13.99% |
| 2014 Q4 | -18.27 Billion KRW | 10.34% |
| 2014 Q3 | -20.37 Billion KRW | 12.72% |
| 2014 Q2 | -23.34 Billion KRW | -10.08% |
| 2013 Q3 | -20.14 Billion KRW | 29.02% |
| 2013 Q2 | -28.37 Billion KRW | -21.82% |
| 2013 Q4 | -16.03 Billion KRW | 20.41% |
| 2013 FY | -16.03 Billion KRW | 23.72% |
| 2013 Q1 | -23.29 Billion KRW | -10.84% |
| 2012 Q1 | -12.65 Billion KRW | 0.0% |
| 2012 FY | -21.01 Billion KRW | -84.18% |
| 2012 Q4 | -21.01 Billion KRW | 0.0% |
| 2011 FY | -11.41 Billion KRW | -26.36% |
| 2011 Q2 | -4.88 Billion KRW | 29.26% |
| 2011 Q1 | -6.9 Billion KRW | 23.57% |
| 2011 Q3 | -7.84 Billion KRW | -60.67% |
| 2010 Q3 | -5.79 Billion KRW | -73.42% |
| 2010 Q1 | 4.37 Billion KRW | -27.1% |
| 2010 FY | -9.03 Billion KRW | -250.61% |
| 2010 Q4 | -9.03 Billion KRW | -55.75% |
| 2010 Q2 | -3.34 Billion KRW | -176.49% |
| 2009 Q3 | -2.38 Billion KRW | -450.58% |
| 2009 FY | 5.99 Billion KRW | 354.29% |
| 2009 Q4 | 5.99 Billion KRW | 351.22% |
| 2009 Q1 | 542.71 Million KRW | 123.02% |
| 2009 Q2 | 680.76 Million KRW | 25.44% |
| 2008 Q3 | 804.18 Million KRW | -37.43% |
| 2008 Q1 | -1.92 Billion KRW | 24.5% |
| 2008 FY | -2.35 Billion KRW | 7.43% |
| 2008 Q2 | 1.28 Billion KRW | 166.84% |
| 2008 Q4 | -2.35 Billion KRW | -393.2% |
| 2007 Q1 | -8.79 Billion KRW | 0.0% |
| 2007 Q4 | -2.54 Billion KRW | 70.71% |
| 2007 FY | -2.54 Billion KRW | 0.0% |
| 2007 Q2 | -8.07 Billion KRW | 8.18% |
| 2007 Q3 | -8.69 Billion KRW | -7.64% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -1218.606% |
| Dong-A Socio Holdings Co., Ltd. | 572.02 Billion KRW | 79.709% |
| Ildong Holdings Co., Ltd. | 310.87 Billion KRW | 62.664% |
| HANDOK Inc. | 283.45 Billion KRW | 59.053% |
| Kukje Pharma Co., Ltd. | 20.07 Billion KRW | -478.248% |
| Yuhan Corporation | -69.18 Billion KRW | 267.76% |
| Dong-A ST Co., Ltd. | 193.95 Billion KRW | 40.156% |
| SAMSUNG PHARM. Co., LTD. | -3.68 Billion KRW | 3249.02% |
| Hanmi Pharm. Co., Ltd. | 517.88 Billion KRW | 77.588% |
| Hanall Biopharma Co.,Ltd | -32.43 Billion KRW | 457.879% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | -53.376% |
| Dong Sung Bio Pharm.Co.,Ltd. | 36.83 Billion KRW | -215.08% |
| MYUNGMOON Pharm co.,Ltd | 82.52 Billion KRW | -40.653% |
| Hana Pharm Co., Ltd. | 25.1 Billion KRW | -362.264% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -1218.606% |
| Ilsung Pharmaceuticals Co., Ltd. | -159.84 Billion KRW | 172.611% |
| REYON Pharmaceutical Co., Ltd. | 200.94 Billion KRW | 42.24% |
| Aprogen pharmaceuticals,Inc. | 170.94 Billion KRW | 32.102% |
| JW Holdings Corporation | 480.68 Billion KRW | 75.854% |
| Ildong Pharmaceutical Co., Ltd. | 164.58 Billion KRW | 29.478% |
| Chong Kun Dang Pharmaceutical Corp. | 117.53 Million KRW | -98654.041% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 24.813% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -4836.253% |
| Hyundai Pharmaceutical Co., Ltd. | 23 Billion KRW | -404.608% |
| Samil Pharmaceutical Co.,Ltd | 174.97 Billion KRW | 33.666% |
| Jeil Pharmaceutical Co.,Ltd | 51.97 Billion KRW | -123.315% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -1218.606% |
| Kwang Dong Pharmaceutical Co., Ltd. | 158.29 Billion KRW | 26.678% |
| Daewoong pharmaceutical Co.,Ltd | 358.17 Billion KRW | 67.595% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 24.813% |
| Yuhan Corporation | -69.18 Billion KRW | 267.76% |
| Jeil Pharma Holdings Inc | 135.99 Billion KRW | 14.651% |
| Yungjin Pharm. Co., Ltd. | 59.67 Billion KRW | -94.501% |
| Suheung Co., Ltd. | 429.14 Billion KRW | 72.954% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 24.813% |
| Samjin Pharmaceuticals Co., Ltd. | 116.23 Billion KRW | 0.146% |
| Korea United Pharm Inc. | 16.42 Billion KRW | -606.644% |
| CKD Bio Corp. | 143.29 Billion KRW | 19.002% |
| Dongwha Pharm.Co.,Ltd | -24.06 Billion KRW | 582.372% |
| Whan In Pharm Co.,Ltd. | -44.73 Billion KRW | 359.46% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -4836.253% |
| Chong Kun Dang Holdings Corp. | 422.84 Billion KRW | 72.551% |
| Boryung Corporation | 187.72 Billion KRW | 38.173% |
| Bukwang Pharmaceutical Co., Ltd. | -71.84 Billion KRW | 261.563% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | -53.376% |
| JW Lifescience Corporation | 26.09 Billion KRW | -344.86% |